• Neogen Corporation recently reported past second-quarter fiscal 2026 results showing revenue of US$224.69 million versus US$231.26 million a year earlier, with the quarterly net loss shrinking to US$15.92 million and first-half fiscal net income reaching US$20.41 million.
• The company also raised its full-year 2026 revenue outlook to US$845 million–US$855 million and outlined cost-saving initiatives, portfolio divestitures, and new senior leadership appointments to reshape its Food Safety operations and global commercial execution.
• We’ll now examine how Neogen’s raised full-year revenue guidance and ongoing cost-savings program influence the company’s overall investment narrative.

We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Neogen Investment Narrative Recap

To own Neogen, you need to believe that tighter global food safety standards will keep supporting demand for its testing and diagnostics, while management restores profitability after past integration issues. The raised full year 2026 revenue outlook and early progress on cost savings support that near term earnings stabilization is a key catalyst, but portfolio divestitures and execution on efficiency gains remain the biggest current risks to the story.

Among the recent updates, the plan to achieve about US$20 million in annualized cost savings is most relevant here, because it directly targets the operational inefficiencies that have weighed on margins. If Neogen can capture these savings while simplifying its portfolio and integrating the Petrifilm line as planned, the improved earnings profile could become more aligned with its sharpened focus on Food Safety and Animal Safety testing demand.

Yet, against this improving guidance, investors should be aware that ongoing portfolio divestitures could still...

Neogen's narrative projects $859.1 million revenue and $107.3 million earnings by 2028. This assumes a 1.3% yearly revenue decline and an earnings increase of about $1.2 billion from -$1.1 billion today.

Uncover how Neogen's forecasts yield a $8.17 fair value, a 13% downside to its current price.

Exploring Other Perspectives

Simply Wall St Community members currently place Neogen’s fair value between US$8.17 and US$14.15, across 2 individual views. Against that diversity of opinions, the emphasis on cost savings and operational fixes highlights how much of the company’s performance still depends on execution that investors will want to assess from several angles.

Explore 2 other fair value estimates on Neogen - why the stock might be worth as much as 51% more than the current price!

Build Your Own Neogen Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Neogen research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Neogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neogen's overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Outshine the giants: these 26 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.